---
title: "AIM ImmunoTech Inc. (AIM.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AIM.US/overview.md"
symbol: "AIM.US"
name: "AIM ImmunoTech Inc."
parent: "https://longbridge.com/en/quote/AIM.US.md"
datetime: "2026-04-15T19:18:47.670Z"
locales:
  - [en](https://longbridge.com/en/quote/AIM.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AIM.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AIM.US/overview.md)
---

# AIM ImmunoTech Inc. (AIM.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 2117 SW Highway 484, Ocala, Florida, United States |
| Website | [aimimmuno.com](https://aimimmuno.com) |

## Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc.

## Key Executives

| Name | Title |
|------|-------|
| Thomas K. Equels | Executive Vice Chairman, CEO & President |
| William M. Mitchell | Independent Chairman of the Board & Member of Scientific Advisory Board |
| Robert Dickey | Chief Financial Officer |
| Peter W. Rodino | COO, Executive Director of Governmental Relations, General Counsel & Secretary |
| Ann Marie E. Coverly | Director of Administration & Human Resources and Deputy Investor Relations Coordinator |
| Christopher Nicodemus | Member of Scientific Advisory Board & Consulting Science Officer |
| W. Neal Burnette | Chairman of Scientific Advisory Board |
| Nancy K. Bryan | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| DRW Holdings, LLC | 0.85% | 2025-12-31 |
| Thomas K. Equels | 0.78% | 2026-03-12 |
| Ted Douglas Kellner | 0.46% | 2025-10-24 |
| Armistice Capital LLC | 0.41% | 2024-12-31 |
| David I. Chemerow | 0.35% | 2026-03-12 |
| The Vanguard Group, Inc. | 0.22% | 2025-12-31 |
| Geode Capital Management, LLC | 0.21% | 2025-12-31 |
| Todd A. Deutsch | 0.21% | 2024-12-19 |
| William M. Mitchell | 0.06% | 2025-10-24 |
| Peter W. Rodino | 0.05% | 2025-10-24 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Clinical Development of New Drug Therapies Based on Natural Immune System | 88000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "AIM ImmunoTech Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Clinical Development of New Drug Therapies Based on Natural Immune System",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 88000 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**